UroGen Pharma To Ring The Nasdaq Stock Market Opening Bell
Published: Jun 02, 2017
RA’ANANA, Israel and NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie Belldegrun, MD, UroGen's Chairman, and Ron Bentsur, the Company’s Chief Executive Officer, along with other members of the management team, will ring the Nasdaq stock market opening bell on Thursday, June 8, 2017, in celebration of the Company’s recently completed initial public offering.
“We are excited to celebrate our recently completed IPO and listing on the Nasdaq global market, one of the world’s largest trading platforms,” said Ron Bentsur, Chief Executive Officer of UroGen. “The closing of our IPO was an important milestone for the Company as we continue to advance our portfolio of product candidates to address unmet needs in the fields of uro-oncology and urology.”
A live webcast of the ceremony will be available at https://livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx from approximately 9:15 a.m. to 9:30 a.m. EDT.
About UroGen Pharma Ltd.
UroGen Pharma (NASDAQ:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACTS: UroGen Pharma Ltd. Gary Titus Chief Financial Officer email@example.com 646-768-9531 Or Burns McClellan, Inc. Steve Klass firstname.lastname@example.org 212-213-0006